Related Experiment Videos

Genetic polymorphisms that predict outcome and need for treatment in cardiovascular disease

Sachin Yende1, Richard G Wunderink

  • 1Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Current Opinion in Critical Care
|September 1, 2006
PubMed

Insights

Genetic research is uncovering specific genotypes linked to cardiovascular disease complications and guiding personalized management strategies. Discovering these genetic risks is crucial for tailoring treatments and improving patient outcomes.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Pharmacogenomics

Background:

  • Growing interest in genetic factors influencing cardiovascular disease (CVD) complications and their impact on treatment.
  • Previous research focused on CVD susceptibility, necessitating a shift towards understanding complication risks.
  • The need for literature review on genetic determinants of CVD complications and management differences.

Purpose of the Study:

  • To review recent literature (12-16 months) on genetic risk factors for cardiovascular disease complications.
  • To identify genetic associations influencing the management of cardiovascular disease.
  • To focus on genetic predispositions to complications rather than solely CVD susceptibility.

Main Methods:

  • Literature review of studies published within the last 12-16 months.
  • Analysis of genetic polymorphisms associated with cardiovascular disease complications.
  • Examination of genotype-specific therapeutic approaches and outcomes.

Main Results:

  • Polymorphisms in MEF2A, TNFSF4, and PCSK9 are linked to altered risks of coronary artery disease and myocardial infarction.
  • Genotype-specific therapy targeting the 5-lipoxygenase pathway showed reduced inflammatory markers in high-risk patients.
  • Genetic polymorphisms are associated with bleeding and renal complications post-coronary artery bypass surgery.
  • Familial studies confirm genetic links to thoracic aortic aneurysms.

Conclusions:

  • Familial risk for cardiovascular disease is established, with specific at-risk genotypes being increasingly identified.
  • Advances in genetic science are making genotype-specific interventions increasingly feasible.
  • Understanding genetic determinants is key to advancing personalized cardiovascular medicine.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...